Fortress Biotech's Network Flex Business Model

By Ben Comer, Chief Editor, Life Science Leader

When the very first clinical data are peer-reviewed and published from a first-in-human trial of a new experimental drug candidate, it’s probably too late for Lindsay Rosenwald, chairman, president, and CEO of Fortress Biotech, to make an offer. “If a banker is shopping an opportunity, where is my competitive advantage? If it’s a really good drug, somebody’s going to pay up for it, and we try to avoid bidding wars.”

For more than 30 years, Rosenwald, an MD, financial manager, and biopharma company founder and investor, has been hunting for novel drug candidates to invest in, or to purchase directly and build companies around. During that time, Rosenwald meticulously cultivated a network of advisers, academics, and scientific experts, which he relies on to help identify promising clinical-stage drug candidates in areas of unmet need, before others find out about them.